MX2018002633A - Formulaciones de pirofosfato férrico solido soluble, kits y métodos de uso de las mismas. - Google Patents

Formulaciones de pirofosfato férrico solido soluble, kits y métodos de uso de las mismas.

Info

Publication number
MX2018002633A
MX2018002633A MX2018002633A MX2018002633A MX2018002633A MX 2018002633 A MX2018002633 A MX 2018002633A MX 2018002633 A MX2018002633 A MX 2018002633A MX 2018002633 A MX2018002633 A MX 2018002633A MX 2018002633 A MX2018002633 A MX 2018002633A
Authority
MX
Mexico
Prior art keywords
ferric pyrophosphate
soluble ferric
kits
methods
same
Prior art date
Application number
MX2018002633A
Other languages
English (en)
Spanish (es)
Inventor
Chioini Robert
Gupta Ajay
Original Assignee
Rockwell Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockwell Medical Inc filed Critical Rockwell Medical Inc
Publication of MX2018002633A publication Critical patent/MX2018002633A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A61M1/1656—Apparatus for preparing dialysates
    • A61M1/1666—Apparatus for preparing dialysates by dissolving solids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
MX2018002633A 2015-09-04 2016-09-02 Formulaciones de pirofosfato férrico solido soluble, kits y métodos de uso de las mismas. MX2018002633A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562214908P 2015-09-04 2015-09-04
PCT/US2016/050120 WO2017040937A1 (en) 2015-09-04 2016-09-02 Solid soluble ferric pyrophosphate formulations, kits, and methods using the same

Publications (1)

Publication Number Publication Date
MX2018002633A true MX2018002633A (es) 2019-02-07

Family

ID=56926337

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002633A MX2018002633A (es) 2015-09-04 2016-09-02 Formulaciones de pirofosfato férrico solido soluble, kits y métodos de uso de las mismas.

Country Status (18)

Country Link
US (1) US11517555B2 (OSRAM)
EP (1) EP3344235A1 (OSRAM)
JP (1) JP7055738B2 (OSRAM)
KR (1) KR20180050346A (OSRAM)
CN (1) CN108601738A (OSRAM)
AU (1) AU2016315877B2 (OSRAM)
BR (1) BR112018004244A2 (OSRAM)
CA (1) CA2997328A1 (OSRAM)
CL (1) CL2018000566A1 (OSRAM)
CO (1) CO2018002421A2 (OSRAM)
EA (1) EA201890642A1 (OSRAM)
IL (1) IL257796B (OSRAM)
MX (1) MX2018002633A (OSRAM)
PE (1) PE20181162A1 (OSRAM)
PH (1) PH12018500463A1 (OSRAM)
SG (1) SG10202107245UA (OSRAM)
UA (1) UA124923C2 (OSRAM)
WO (1) WO2017040937A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN110063965A (zh) * 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
FR3109734B1 (fr) * 2020-05-04 2025-04-11 Univ Claude Bernard Lyon Système de dialyse pour le traitement du sepsis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177068A (en) * 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
CA2234957C (en) * 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
US6779468B1 (en) 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
JP3778240B2 (ja) 1998-06-22 2006-05-24 ライオン株式会社 不快な味がマスキングされた造粒組成物及びその製造方法
WO2000016873A1 (en) 1998-09-18 2000-03-30 Rockwell Medical Technologies, Inc. Method and apparatus for preparing liquid dialysate
JP5102423B2 (ja) * 2000-04-20 2012-12-19 オバン・エナジー・リミテッド 改善された水不溶性薬剤粒子の処理
JP2002302435A (ja) 2000-12-26 2002-10-18 Takeda Chem Ind Ltd 多孔性物質およびその製造法
EP1354581A4 (en) 2000-12-26 2007-07-04 Takeda Pharmaceutical POROUS SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
US7857977B2 (en) 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
ATE522151T1 (de) * 2005-07-15 2011-09-15 Unilever Nv Eisen verstärktes lebensmittel und zusatzstoff
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
WO2012092305A2 (en) * 2010-12-27 2012-07-05 Incube Labs, Llc Nanonized iron compositions and methods of use thereof
BR112015018549A8 (pt) 2013-02-01 2018-01-30 Charak Llc métodos de tratamento de deficiência de ferro

Also Published As

Publication number Publication date
KR20180050346A (ko) 2018-05-14
US20180243256A1 (en) 2018-08-30
US11517555B2 (en) 2022-12-06
UA124923C2 (uk) 2021-12-15
PE20181162A1 (es) 2018-07-19
BR112018004244A2 (pt) 2018-09-25
CO2018002421A2 (es) 2018-07-19
CL2018000566A1 (es) 2018-08-03
EP3344235A1 (en) 2018-07-11
WO2017040937A1 (en) 2017-03-09
AU2016315877A1 (en) 2018-04-05
SG10202107245UA (en) 2021-08-30
CA2997328A1 (en) 2017-03-09
CN108601738A (zh) 2018-09-28
EA201890642A1 (ru) 2018-10-31
JP7055738B2 (ja) 2022-04-18
PH12018500463A1 (en) 2018-09-17
IL257796A (en) 2018-04-30
IL257796B (en) 2021-09-30
JP2018529674A (ja) 2018-10-11
AU2016315877B2 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2020001555A (es) Preparaciones terapéuticas de glicanos y métodos relacionados con estas.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MY187540A (en) Compounds active towards bromodomains
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2015012416A (es) Compuestos heterociclicos y sus usos.
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MY191539A (en) Streptococcal vaccine
NZ702369A (en) Treatment of solid tumors using coenzyme q10
EP3349755A4 (en) NICOTINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
IL262929A (en) Composition, and application and pharmaceutical preparation thereof
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
PH12018500463A1 (en) Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
MX345263B (es) Formulación de pexiganan estable.
MX2016015017A (es) Composiciones dentifricas con estabilidad mejorada del fluoruro.
PH12018501166B1 (en) Concentrated gibberellin solution formulations
PL3145490T3 (pl) Liposomy zawierające kwas dihomo-gamma-linolenowy (dgla), zawierające je preparaty i ich zastosowanie
UA66165U (ru) Применение витаминной композиции, которая содержит витамины С и К3, в качестве средства для лечения вирусных инфекций